This workstream will apply advanced in vitro infections models, such as the hollow fibre infection model, to characterise the relationship between antimicrobial exposures and the emergence of antimicrobial resistance.  

Dynamic bacterial-kill studies will be led by Workstream 2 Lead, A/Prof Cornelia Landersdorfer, and she will be responsible for collating Dynamic bacterial-kill studies’ status, progress and milestone reports and ensuring they are escalated to the Operations Committee or Steering Committee for consideration and advice.

The objective of this workstream is to apply in vitro hollow-fibre infection model methods to quantify how antimicrobial exposure leads to emergence of antimicrobial resistance in patients.

Workstream 2: Dynamic bacterial-kill studies
Project Lead
ELF  Gram-negative
In vitro evaluation of the impact of antimicrobial exposure profiles in ELF on bacterial killing and suppression of resistance emergence for critical Gram-negative bacteria
Duration of exposure 
In vitro evaluation of the impact of different durations of exposure of fast-acting antimicrobials in combination with beta-lactams
P. MDR P. aeruginosa CF 
In vitro optimisation of combination antimicrobial therapy for acute exacerbations of chronic infections with MDR P. aeruginosa in patients with cystic fibrosis